TY - JOUR
T1 - Fatigue performance and cyto-toxicity of low rigidity titanium alloy, Ti-29Nb-13Ta-4.6Zr
AU - Niinomi, Mitsuo
N1 - Funding Information:
Some parts of this study were supported by NEDO (New Energy and Industrial Technology Development Organization, Tokyo, Japan), Grant-in-Aid for Promoting Scientific Frontier Research from Ministry Education, Science and Culture (Tokyo, Japan), Grant-in-Aid for Scientific Research from Japan Society for Promotion of Science (Tokyo, Japan), Mitsubishi Foundation (Tokyo, Japan), Kotai Foundation (Toyohashi, Japan), The Iron and Steel Institute of Japan (Tokyo, Japan), The Light Metal Education Foundation (Osaka, Japan), and Suzuki Foundation (Hamamatsu, Japan).
PY - 2003/7
Y1 - 2003/7
N2 - A β type titanium alloy, Ti-29Nb-13Ta-4.6Zr, was newly designed and developed for biomedical applications. The new alloy contains non-toxic elements such as Nb, Ta, and Zr. In the present study, phases that appeared in the new alloy through various aging treatments were characterized by hardness tests and microstructural observations in order to identify the phase transformation. Fatigue properties of the new alloy were investigated. Young's modulus and cyto-toxicity of the new alloy were also evaluated. Precipitated phases distribute homogeneously over the whole specimen, and they are α phase, a small amount of ω phase, and β phase when the new alloys are subjected to aging treatment at 673K for 259.2ks after solution treatment at 1063K for 3.6ks. The fatigue strength of the new alloy subjected to aging at 673K for 259.2ks after solution treatment at 1063K for 3.6ks is much better than when subjected to other aging treatments. In this case, the fatigue limit is around 700MPa. Young's modulus of the new alloy is much smaller than that of Ti-6Al-4V ELI. The cyto-toxicity of the new alloy is equivalent to that of pure Ti. Therefore, it is proposed that the new alloy, Ti-29Nb-13Ta-4.6Zr, will be of considerable use in biomedical applications.
AB - A β type titanium alloy, Ti-29Nb-13Ta-4.6Zr, was newly designed and developed for biomedical applications. The new alloy contains non-toxic elements such as Nb, Ta, and Zr. In the present study, phases that appeared in the new alloy through various aging treatments were characterized by hardness tests and microstructural observations in order to identify the phase transformation. Fatigue properties of the new alloy were investigated. Young's modulus and cyto-toxicity of the new alloy were also evaluated. Precipitated phases distribute homogeneously over the whole specimen, and they are α phase, a small amount of ω phase, and β phase when the new alloys are subjected to aging treatment at 673K for 259.2ks after solution treatment at 1063K for 3.6ks. The fatigue strength of the new alloy subjected to aging at 673K for 259.2ks after solution treatment at 1063K for 3.6ks is much better than when subjected to other aging treatments. In this case, the fatigue limit is around 700MPa. Young's modulus of the new alloy is much smaller than that of Ti-6Al-4V ELI. The cyto-toxicity of the new alloy is equivalent to that of pure Ti. Therefore, it is proposed that the new alloy, Ti-29Nb-13Ta-4.6Zr, will be of considerable use in biomedical applications.
KW - Beta titanium alloy
KW - Biomedical application
KW - Cyto-toxicity
KW - Fatigue
KW - Low rigidity
KW - Ti-29Nb-13Ta-4.6Zr
UR - http://www.scopus.com/inward/record.url?scp=0037411338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037411338&partnerID=8YFLogxK
U2 - 10.1016/S0142-9612(03)00069-3
DO - 10.1016/S0142-9612(03)00069-3
M3 - Article
C2 - 12711513
AN - SCOPUS:0037411338
VL - 24
SP - 2673
EP - 2683
JO - Biomaterials
JF - Biomaterials
SN - 0142-9612
IS - 16
ER -